BR9714349A - L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos - Google Patents
L-nucleosìdeos purina, seus análogos e utilizacões dos mesmosInfo
- Publication number
- BR9714349A BR9714349A BR9714349-9A BR9714349A BR9714349A BR 9714349 A BR9714349 A BR 9714349A BR 9714349 A BR9714349 A BR 9714349A BR 9714349 A BR9714349 A BR 9714349A
- Authority
- BR
- Brazil
- Prior art keywords
- purine
- compounds
- nucleosides
- analogues
- compositions
- Prior art date
Links
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title abstract 6
- 239000002777 nucleoside Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061217 Infestation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
Abstract
Patente de Invenção: <B>''L-NUCLEOSìDEOS PURINA, SEUS ANáLOGOS E UTILIZAçõES DOS MESMOS''<D>. Estão descritos novos compostos do L-nucleosídeo purina, em que ambos ou um ou outro dos anéis de purina e de açúcar são modificados, funcionalizados, ou ambos. Os compostos, ou os ésteres ou sais farmaceuticamente aceitáveis dos mesmos podem ser utilizados em composições farmacêuticas, e tais composições podem ser utilizadas para o tratamento de uma infecção, uma infestação, um neoplasma, ou uma doença auto-imune.. Os compostos também podem ser utilizados para modular aspectos do sistema imune, incluindo modulações de Th1 e Th2.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2858696P | 1996-10-16 | 1996-10-16 | |
US4397497P | 1997-04-23 | 1997-04-23 | |
US5548797P | 1997-08-12 | 1997-08-12 | |
PCT/US1997/018387 WO1998016184A2 (en) | 1996-10-16 | 1997-10-15 | Purine l-nucleosides, analogs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9714349A true BR9714349A (pt) | 2000-11-14 |
Family
ID=27363301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9714349-9A BR9714349A (pt) | 1996-10-16 | 1997-10-15 | L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos |
Country Status (21)
Country | Link |
---|---|
US (1) | US20020058635A1 (pt) |
EP (1) | EP0961775B1 (pt) |
JP (2) | JP2001524936A (pt) |
KR (2) | KR100386140B1 (pt) |
CN (3) | CN1233254A (pt) |
AT (1) | ATE271063T1 (pt) |
AU (1) | AU727177B2 (pt) |
BR (1) | BR9714349A (pt) |
CA (1) | CA2266889A1 (pt) |
CZ (1) | CZ126799A3 (pt) |
DE (1) | DE69729887T2 (pt) |
HK (1) | HK1021738A1 (pt) |
HU (1) | HUP0001186A3 (pt) |
IL (1) | IL129118A0 (pt) |
NO (3) | NO991784L (pt) |
PL (1) | PL188660B1 (pt) |
SI (1) | SI20024A (pt) |
SK (1) | SK48199A3 (pt) |
UA (1) | UA63984C2 (pt) |
WO (1) | WO1998016184A2 (pt) |
YU (1) | YU18899A (pt) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455690B1 (en) * | 1996-10-16 | 2002-09-24 | Robert Tam | L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine |
AU743366B2 (en) * | 1997-01-17 | 2002-01-24 | Icn Pharmaceuticals, Inc. | Novel nucleosides |
GB9821058D0 (en) | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
BR0013642A (pt) * | 1999-08-27 | 2002-05-07 | Icn Pharmaceuticals | Análogos de nucleosìdeo de pirrolo[2,3-d]pirimidina |
US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
ATE414520T1 (de) | 2000-04-13 | 2008-12-15 | Pharmasset Inc | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
KR20080021797A (ko) | 2000-05-26 | 2008-03-07 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
RU2286172C2 (ru) | 2000-08-17 | 2006-10-27 | Трипеп Аб | Вакцины, содержащие рибавирин, и способы их использования |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
CA2419418A1 (en) | 2000-08-17 | 2002-02-21 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
JP4524072B2 (ja) * | 2000-10-23 | 2010-08-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規化合物 |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
US7049303B2 (en) | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
CN1300165C (zh) * | 2001-11-27 | 2007-02-14 | 安那迪斯药品股份有限公司 | 3-β-呋喃核糖基噻唑并[4,5-d]嘧啶核苷及其应用 |
US7321033B2 (en) * | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
US20030153744A1 (en) * | 2001-12-21 | 2003-08-14 | Micrologix Biotech Inc. | Anti-viral 7-deaza L-nucleosides |
CN104193791A (zh) * | 2002-06-28 | 2014-12-10 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
AU2003257157C1 (en) | 2002-08-01 | 2010-03-18 | Pharmasset Inc. | Compounds with the bicyclo[4.2.1] nonane system for the treatment of Flaviviridae infections |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
CN1293884C (zh) * | 2002-10-29 | 2007-01-10 | 南京长澳医药科技有限公司 | 6-甲氧基双脱氧鸟苷在制备抗乙肝药物中的应用 |
EP1576138B1 (en) | 2002-11-15 | 2017-02-01 | Idenix Pharmaceuticals LLC. | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
US20050049204A1 (en) * | 2003-03-28 | 2005-03-03 | Otto Michael J. | Compounds for the treatment of flaviviridae infections |
DE10320785A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
US8044060B2 (en) | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
US7550442B2 (en) * | 2003-05-20 | 2009-06-23 | The Board Of Trustees Of The University Of Illinois | Nucleoside analog inhibitors of reverse transcriptase |
WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
BR122018015050B1 (pt) * | 2003-05-30 | 2021-07-13 | Gilead Pharmasset Llc | Derivados fosfatados de nucleosídeo e composição farmacêutica dos mesmos |
CN1852915A (zh) | 2003-07-25 | 2006-10-25 | 艾登尼科斯(开曼)有限公司 | 治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物 |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
BRPI0415373A (pt) | 2003-10-14 | 2006-12-12 | Intermune Inc | ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv |
DE102004001873A1 (de) * | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
MX2007001589A (es) * | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas. |
US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
ES2725457T3 (es) * | 2004-09-14 | 2019-09-24 | Gilead Pharmasset Llc | Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados |
WO2006050161A2 (en) | 2004-10-29 | 2006-05-11 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
CN102504001B (zh) | 2004-12-17 | 2015-02-25 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
AU2006205851A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
US7947694B2 (en) | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors |
WO2006097547A1 (es) * | 2005-03-17 | 2006-09-21 | Proyecto De Biomedicina Cima S.L. | Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes |
AU2006229995A1 (en) * | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives |
PE20061351A1 (es) | 2005-03-25 | 2007-01-14 | Glaxo Group Ltd | COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38 |
EP1907407A1 (en) * | 2005-07-22 | 2008-04-09 | Giuliani International Limited | Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation |
ITRM20050391A1 (it) * | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione. |
DE602006015700D1 (de) | 2005-11-21 | 2010-09-02 | Anadys Pharmaceuticals Inc | Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on |
BRPI0713680A2 (pt) * | 2006-06-22 | 2012-10-23 | Anadys Pharmaceuticals Inc | composto, composição farmacêutica e métodos de modulação das atividades imuno da citocina, de tratamento de infecção de vìrus da hepatite c em paciente e de tratamento de desordem de proliferação relacionada em mamìfero carecido do mesmo |
ATE499940T1 (de) | 2006-07-18 | 2011-03-15 | Anadys Pharmaceuticals Inc | Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen |
KR20090057035A (ko) * | 2006-08-21 | 2009-06-03 | 유나이티드 세러퓨틱스 코오포레이션 | 바이러스 감염의 치료를 위한 병용 요법 |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
EP2048151A1 (en) * | 2007-10-10 | 2009-04-15 | Cilag AG | Method for producing nucleosides by direct glycosylation of the nucleoside base |
CA2706018C (en) | 2007-11-30 | 2015-11-24 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders |
US8227431B2 (en) | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
ES2329327B1 (es) | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
US20100004526A1 (en) * | 2008-06-04 | 2010-01-07 | Eigen, Inc. | Abnormality finding in projection images |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
US8470834B2 (en) * | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
WO2010027935A1 (en) | 2008-09-08 | 2010-03-11 | Merck Sharp & Dohme Corp. | Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia |
US9079905B2 (en) | 2008-09-08 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Compounds for the treatment of CNS disorders |
WO2010039801A2 (en) | 2008-10-02 | 2010-04-08 | The J. David Gladstone Institutes | Methods of treating hepatitis c virus infection |
KR20110104074A (ko) | 2008-12-23 | 2011-09-21 | 파마셋 인코포레이티드 | 퓨린 뉴클레오시드의 합성 |
AU2009329867B2 (en) | 2008-12-23 | 2015-01-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
CN102753563A (zh) | 2008-12-23 | 2012-10-24 | 吉利德制药有限责任公司 | 核苷类似物 |
WO2010107739A2 (en) | 2009-03-18 | 2010-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a flaviviridae family viral infection |
MY156377A (en) | 2009-03-31 | 2016-02-15 | Boehringer Ingelheim Int | 1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
AR077859A1 (es) | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | Compuestos para el tratamiento de trastornos del snc |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
EP2752422B1 (en) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
WO2012004917A1 (ja) * | 2010-07-06 | 2012-01-12 | Kaminishi Hidenori | 神経突起伸長剤 |
GEP20156217B (en) | 2010-08-12 | 2015-01-12 | Boehringer Ingelheim Int | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9408863B2 (en) | 2011-07-13 | 2016-08-09 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CN104066432B (zh) | 2011-12-06 | 2017-06-13 | 小利兰·斯坦福大学董事会 | 用于治疗病毒性疾病的方法和组合物 |
RS58099B1 (sr) | 2011-12-22 | 2019-02-28 | Alios Biopharma Inc | Supstituisani nukleozidi, nukleotidi i njihovi analozi |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
ES2597757T3 (es) | 2012-05-25 | 2017-01-20 | Janssen Sciences Ireland Uc | Nucleósidos de uracilespirooxetano |
EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
WO2014120981A1 (en) | 2013-01-31 | 2014-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
EP3038601B1 (en) | 2013-08-27 | 2020-04-08 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
WO2015054465A1 (en) | 2013-10-11 | 2015-04-16 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
RU2695664C1 (ru) * | 2013-12-09 | 2019-07-25 | Юсб Байофарма Спрл | Производные имидазопиридина в качестве модуляторов активности tnf |
WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
CN104497083B (zh) * | 2014-05-12 | 2017-07-07 | 河南师范大学 | 具有抗寄生虫活性的核苷‑苯基丙烯酮杂化体及其制备方法和应用 |
JP6671355B2 (ja) | 2014-09-26 | 2020-03-25 | リボサイエンス・エルエルシー | 呼吸器多核体ウイルスのrna複製の阻害剤としての4’‐ビニル置換ヌクレオシド誘導体 |
AU2015359692B2 (en) | 2014-12-08 | 2020-07-09 | F. Hoffmann-La Roche Ag | 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection |
CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
EP3695837A1 (en) | 2015-03-16 | 2020-08-19 | F. Hoffmann-La Roche AG | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
CN107743491B (zh) | 2015-05-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物 |
EP4001283A1 (en) | 2015-05-12 | 2022-05-25 | F. Hoffmann-La Roche AG | Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection |
CN104844673B (zh) * | 2015-06-04 | 2017-09-08 | 新乡学院 | 一种制备天然核苷水粉蕈素的方法 |
WO2017001307A1 (en) | 2015-06-30 | 2017-01-05 | F. Hoffmann-La Roche Ag | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection |
RU2720811C2 (ru) | 2015-09-23 | 2020-05-13 | Мерк Шарп И Доум Лимитед | 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение |
PT3433257T (pt) | 2016-03-24 | 2023-11-29 | Novartis Ag | Análogos nucleosídeos de alquinil como inibidores do rinovírus humano |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
LT3512863T (lt) | 2016-09-07 | 2022-03-10 | Atea Pharmaceuticals, Inc. | 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu |
CN110139868B (zh) | 2017-01-06 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法 |
CN108329372B (zh) * | 2017-01-20 | 2022-07-26 | 浙江省亚热带作物研究所 | N6-(2-羟乙基)腺苷及其衍生物在制备治疗痛风药物中的应用 |
GEP20237457B (en) | 2017-02-01 | 2023-01-10 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for treatment of hepatitis c virus |
US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
TW202012001A (zh) | 2018-04-10 | 2020-04-01 | 美商亞堤製藥公司 | C型肝炎病毒(hcv)感染硬化之患者的治療 |
EP3801538A4 (en) | 2018-05-25 | 2022-03-09 | Primmune Therapeutics, Inc. | TLR7 AGONISTS |
BR112021019465A8 (pt) | 2019-04-02 | 2022-06-07 | Aligos Therapeutics Inc | Compostos que têm como alvo prmt5 |
CN111973615A (zh) * | 2019-05-22 | 2020-11-24 | 华东理工大学 | 一种治疗躁狂型精神障碍及精神分裂症的药物 |
CA3163093A1 (en) | 2019-11-26 | 2021-06-03 | Primmune Therapeutics, Inc. | Tlr7 agonists |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
US11780840B2 (en) | 2020-07-02 | 2023-10-10 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166141A (en) * | 1983-11-01 | 1992-11-24 | Scripps Clinic And Research Foundation | Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals |
EP0285884A3 (en) * | 1987-03-20 | 1990-07-04 | Bristol-Myers Squibb Company | process to produce 2', 3'-dideoxynucleosides |
US5041426A (en) * | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
SE9003151D0 (sv) * | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
AU4134793A (en) * | 1992-06-22 | 1993-12-23 | Eli Lilly And Company | 2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates |
US5627160A (en) * | 1993-05-25 | 1997-05-06 | Yale University | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
TW374087B (en) * | 1993-05-25 | 1999-11-11 | Univ Yale | L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents |
FI932943A (fi) * | 1993-06-24 | 1994-12-25 | Irri Oy | Automaattinen työkalunvaihto |
US5567689A (en) * | 1993-08-13 | 1996-10-22 | The Uab Research Foundation | Methods for increasing uridine levels with L-nucleosides |
US5599796A (en) * | 1993-12-02 | 1997-02-04 | Emory University | Treatment of urogenital cancer with boron neutron capture therapy |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
US5559101A (en) * | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
US5672594A (en) * | 1994-10-24 | 1997-09-30 | Genencor International, Inc. | L-erythrosyl nucleosides |
EP0943031A4 (en) * | 1996-08-07 | 1999-11-10 | Henkel Corp | NON-SOLVENT POLYESTER DYE AUXILIARY |
US6509320B1 (en) * | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
-
1997
- 1997-10-15 SI SI9720067A patent/SI20024A/sl unknown
- 1997-10-15 CA CA002266889A patent/CA2266889A1/en not_active Abandoned
- 1997-10-15 AU AU48999/97A patent/AU727177B2/en not_active Ceased
- 1997-10-15 AT AT97911684T patent/ATE271063T1/de not_active IP Right Cessation
- 1997-10-15 JP JP51847598A patent/JP2001524936A/ja not_active Withdrawn
- 1997-10-15 WO PCT/US1997/018387 patent/WO1998016184A2/en not_active Application Discontinuation
- 1997-10-15 DE DE69729887T patent/DE69729887T2/de not_active Expired - Fee Related
- 1997-10-15 KR KR10-2000-7014248A patent/KR100386140B1/ko not_active IP Right Cessation
- 1997-10-15 KR KR10-1999-7003276A patent/KR100412480B1/ko not_active IP Right Cessation
- 1997-10-15 PL PL97332694A patent/PL188660B1/pl not_active IP Right Cessation
- 1997-10-15 IL IL12911897A patent/IL129118A0/xx unknown
- 1997-10-15 EP EP97911684A patent/EP0961775B1/en not_active Expired - Lifetime
- 1997-10-15 SK SK481-99A patent/SK48199A3/sk unknown
- 1997-10-15 BR BR9714349-9A patent/BR9714349A/pt not_active IP Right Cessation
- 1997-10-15 CN CN97198831A patent/CN1233254A/zh active Pending
- 1997-10-15 CZ CZ991267A patent/CZ126799A3/cs unknown
- 1997-10-15 HU HU0001186A patent/HUP0001186A3/hu unknown
-
1999
- 1999-04-15 NO NO991784A patent/NO991784L/no not_active Application Discontinuation
- 1999-04-15 YU YU18899A patent/YU18899A/sh unknown
-
2000
- 2000-01-31 HK HK00100589A patent/HK1021738A1/xx not_active IP Right Cessation
- 2000-07-05 UA UA2000073982A patent/UA63984C2/uk unknown
- 2000-07-26 CN CN00122458A patent/CN1286258A/zh active Pending
- 2000-07-26 CN CN00122459A patent/CN1296011A/zh active Pending
- 2000-08-31 NO NO20004328A patent/NO317259B1/no not_active IP Right Cessation
- 2000-08-31 NO NO20004326A patent/NO316895B1/no not_active IP Right Cessation
-
2001
- 2001-04-09 JP JP2001110027A patent/JP2002105096A/ja active Pending
- 2001-10-30 US US10/021,772 patent/US20020058635A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9714349A (pt) | L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos | |
BR0108401A (pt) | Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina | |
TNSN87021A1 (fr) | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant | |
DE3687224T2 (de) | Hemmung vom 5-lipoxygenase-weg. | |
KR900700094A (ko) | 지방산과 모노글리세라이드의 항비루스 및 항세균 활성 | |
RU94046424A (ru) | Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения | |
EA199901031A1 (ru) | Производные бензимидазола | |
BG101118A (en) | Therapeutical compounds | |
RU95106651A (ru) | Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента | |
EA200100127A1 (ru) | Производные фенилксантина | |
DE3650358T2 (de) | Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis. | |
Duebbert et al. | Enterotoxin-induced fluid accumulation during experimental salmonellosis and cholera: involvement of prostaglandin synthesis by intestinal cells | |
BR9807473A (pt) | Tratamentos de doença relacionados à citocina | |
EA199800526A1 (ru) | Производные бензимидазола и их применение для лечения вирусных инфекций | |
ES2105923A1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
BR9807332A (pt) | Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose | |
EP1072607A3 (en) | Purine L-nucleosides, analogs and uses therof | |
IT8548055A1 (it) | Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale | |
KR910001040A (ko) | 항응고요법을 위한 활성물질인 암블리옴민 | |
ES2106025T3 (es) | Analogos de gangliosidos semisinteticos. | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
NOWOTNY et al. | Interferon induction by endotoxin-derived nontoxic polysaccharides | |
RU2141819C1 (ru) | Мазь с интерфероном человеческим лейкоцитарным "интерон" | |
DE520834T1 (de) | PP14 oder Antikörper gegen PP14 enthaltende pharmazeutische Zusammensetzung zur Behandlung von Immunsystemstörungen. | |
ATE80403T1 (de) | Mit benzyliden-3-substituierte kampfergruppenenthaltende polydiorganosiloxane. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1914 DE 11/09/2007. |